Common cold market seen reaching $36.38 billion by 2030

Nov. 19, 2026
Common cold market seen reaching $36.38 billion by 2030
By AI, Created 16:30 UTC, Nov 19, 2026, AGP -

The global common cold market is projected to rise from $26.89 billion in 2025 to $36.38 billion by 2030, according to The Business Research Company. Growth is being driven by rising seasonal flu cases, broader OTC access, and demand for faster, non-drowsy and sugar-free symptom relief.

Why it matters: - The common cold market is tied to recurring, high-volume consumer healthcare demand. - Growth in cold remedies often tracks seasonal flu activity, pharmacy access, and self-care spending. - The forecast suggests steady expansion for OTC medicines, combination therapies and child-focused cold products.

What happened: - The Business Research Company released Common Cold Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the common cold market will grow from $26.89 billion in 2025 to $28.63 billion in 2026. - The report projects the market will reach $36.38 billion by 2030. - The report forecasts a 6.5% CAGR from 2025 to 2026 and a 6.2% CAGR through 2030. - A free sample of the report is available here. - The full report is available here.

The details: - The market’s recent growth has been driven by high seasonal viral infection rates. - Widespread availability of over-the-counter medications has supported demand. - Established retail pharmacy networks continue to support sales. - Consumer preference for self-medication remains a major growth factor. - Demand typically stays elevated during flu seasons. - Rising consumer interest in immune-boosting products is expected to support future growth. - Increasing penetration of online pharmacies is another growth driver. - Demand for sugar-free medication formulations is growing. - Cold remedies targeted at children are expanding. - Ongoing innovation in combination therapies is shaping the market. - Key trends include greater demand for combination cold medications. - The market is shifting toward non-drowsy remedies. - Herbal and natural ingredients are gaining wider use. - OTC treatments are becoming more broadly available. - Fast symptom relief is a growing product focus. - The common cold is a viral infection that mainly affects the upper respiratory tract, including the nose, throat and sinuses. - Rhinoviruses are the most common cause. - Typical symptoms include a runny or congested nose, sore throat, sneezing, coughing and mild fatigue. - The infection spreads through airborne droplets or contact with contaminated surfaces. - Seasonal flu is a key driver because flu-related symptoms increase demand for cold medicines that ease discomfort while the immune system fights infection. - In December 2024, the NHS reported an average of 1,099 flu-related hospitalizations per day in the UK, compared with 243 daily cases in 2023. - The NHS figure was the highest number of flu admissions entering the winter season in at least three years. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The market outlook reflects a mix of recurring illness demand and product innovation rather than a single breakthrough catalyst. - Growth in non-drowsy, sugar-free and natural formulations suggests consumers want symptom relief with fewer tradeoffs. - Stronger online pharmacy penetration could shift more sales away from traditional retail channels. - Asia-Pacific’s faster growth points to expanding healthcare access and consumer demand beyond the mature North American market.

What's next: - The market will likely keep tracking flu activity, seasonal illness patterns and OTC purchasing habits. - Competition is likely to intensify around formulations that promise faster relief and more targeted use cases. - Regional growth in Asia-Pacific may become a bigger driver of global revenue over the forecast period.

The bottom line: - The common cold market is on a steady growth path, with demand supported by seasonal illness, OTC access and continued product innovation.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.